Eloxx Pharmaceuticals initiates Phase 2 clinical trial for ELX-02
Category: #health  By Mateen Dalal  Date: 2019-08-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eloxx Pharmaceuticals initiates Phase 2 clinical trial for ELX-02

Six patients will be registered for the trial and will be treated with ELX-02 for four weeks with three rising dose levels.

Eloxx Pharmaceuticals, Inc., an American biopharmaceutical company focused on the discovery and development of novel therapeutics to treat inherited retinal disorders, cystinosis, cystic fibrosis and other diseases caused by nonsense mutations preventing production of functional proteins, has recently shared that it has started with the Phase 2 clinical trial for ELX-02 (study 003) in cystinosis in Canada.

According to reliable sources, study 003 is a single arm, open label study developed to assess the tolerability, safety, pharmacokinetics (PK) and PD (pharmacodynamics) of subcutaneous (SC) ELX-02 in people with nephropathic cystinosis with minimum 1 nonsense mutation in the cystinosin gene. 

Speaking on the announcement, Dr. Paul Goodyer, Professor of Pediatrics, McGill University, said that the company is excited to initiate ELX-02 to cystinosis patients, a new potential treatment option which has recorded encouraging results in animal and cellular models with dose-dependent reductions in white blood cell cystine levels, a biomarker used to predict clinical benefit and to monitor cysteamine therapy.

He said that there is a high unmet medical need in cystinosis which is identified in infancy, and the emergence of new therapeutic options that could alter the course of this disease could drastically improve the lives of patients.

According to Dr. Greg Williams, PhD, COO, Eloxx Pharmaceuticals, their firm is delighted to initiate the Phase 2 clinical trial for ELX-02 in cystinosis patients with at least one nonsense mutation in Canada and are grateful for the non-dilutive funding and support it has received for this clinical trial from Genome Canada and Genome Quebec.

He added that the company is looking forward to reporting top line data from this trial in early Q4 2019. The firm believes the initial results from their renal impairment study, as well as the results till date offer support both for continuing their clinical development programs and assessing the aptness of their ERSG library for advancement in additional renal disorders, involving cystinuria and autosomal dominant polycystic kidney disease, cites Williams.

Source Credit: https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-announces-initiation-phase-2-clinical

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Delta and Virgin Atlantic to expand transatlantic services by 2020
Delta and Virgin Atlantic to expand transatlantic services by 2020
By Mateen Dalal

This will be the first time that both the carriers will be serving Gatwick airport since their partnership in 2014 British airlines Virgin Atlantic and the American airline Delta recently announced increased services between the US and UK by the yea...

Ola acquires AI firm Pikup.ai to further enhance its deep tech skills
Ola acquires AI firm Pikup.ai to further enhance its deep tech skills
By Mateen Dalal

Startup Pikup.ai utilizes automated technologies like sensor fusion, computer vision, and Artificial Intelligence to offer AI-based solutions for businesses.   Ola is increasing company’s aim on utilizing deep technology and advanced a...

Sonnet to acquire Relief Therapeutics to develop atexakin alfa
Sonnet to acquire Relief Therapeutics to develop atexakin alfa
By Mateen Dalal

Sonnet proposes to pay 7,111,947 common shares and outstanding common stocks to Relief Therapeutics. Sonnet BioTherapeutics, Inc., a biotechnology company that develops innovative biologic drugs, has recently announced that it has entered into an ag...